Gathering and Exploring Scientific Knowledge in Pharmacovigilance

Lopes, Pedro; Nunes, Tiago; Campos, David; Furlong, Laura I.; Bauer-Mehren, Anna; Sanz, Ferrán; Carrascosa, Maria C.; Mestres, Jordi; Kors, Jan A.; Singh, Bharat; Mulligen, Erik M. van; Lei, Johan van der; Diallo, Gayo; Avillach, Paul; Ahlberg, Ernst; Boyer, Scott; Díaz, Carlos; Oliveira, José Luís

doi:10.1371/journal.pone.0083016

Cited by 16 publications

(14 citation statements)

References 45 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29,30 Effort will also be required to address the medico-legal concerns or consequences from delisting a PDDI. 31 Second, given that severe ADEs do occur secondary to PDDIs, we need to prioritize PDDIs based on the probability of occurrence and the magnitude of harm to patients, and subsequently develop remediation plans for specific high-priority PDDIs; therefore, the likelihood of hospitalized patients experiencing significant ADEs is reduced. The most common contraindicated and major PDDIs were due to more commonly used medications, such as opiates and antiinfective agents.…”

Section: Figurementioning

confidence: 99%

Potential Drug−Drug Interactions in Infant, Child, and Adolescent Patients in Children’s Hospitals

Feinstein

Dai²,

Zhong³

et al. 2015

Pediatrics

102

106

View full text Add to dashboard Cite

show abstract

Section: Figurementioning

confidence: 99%

Potential Drug−Drug Interactions in Infant, Child, and Adolescent Patients in Children’s Hospitals

Feinstein

Dai²,

Zhong³

et al. 2015

Pediatrics

102

106

View full text Add to dashboard Cite

show abstract

“…Due to the “curse of attrition” drug side effects are subjects of increasing concerns 1 2 3 4 . In recent years a growing number of side effect databases helped pharmacovigilance efforts 2 5 6 7 8 9 10 . In addition, the prediction of drug side effects was a subject of several excellent network studies.…”

mentioning

confidence: 99%

“…In addition, the prediction of drug side effects was a subject of several excellent network studies. These contributions constructed and analyzed drug—side effect networks 1 8 11 , side effect similarity-based drug—drug networks 12 13 14 , drug target—side effect networks (including correlated drug binding profiles and side effect profiles and protein domain networks) 3 5 7 15 16 , as well as drug—side effect—biological pathway multi-layer networks 9 10 17 18 .…”

mentioning

confidence: 99%

Targets of drugs are generally and targets of drugs having side effects are specifically good spreaders of human interactome perturbations

Perez-Lopez

Szalay

Türei

et al. 2015

Sci Rep

View full text Add to dashboard Cite

Network-based methods are playing an increasingly important role in drug design. Our main question in this paper was whether the efficiency of drug target proteins to spread perturbations in the human interactome is larger if the binding drugs have side effects, as compared to those which have no reported side effects. Our results showed that in general, drug targets were better spreaders of perturbations than non-target proteins, and in particular, targets of drugs with side effects were also better spreaders of perturbations than targets of drugs having no reported side effects in human protein-protein interaction networks. Colorectal cancer-related proteins were good spreaders and had a high centrality, while type 2 diabetes-related proteins showed an average spreading efficiency and had an average centrality in the human interactome. Moreover, the interactome-distance between drug targets and disease-related proteins was higher in diabetes than in colorectal cancer. Our results may help a better understanding of the network position and dynamics of drug targets and disease-related proteins, and may contribute to develop additional, network-based tests to increase the potential safety of drug candidates.

show abstract

“…Pharmaceutical companies' competition along with rigorous regulatory evaluation procedures empowers a complex research and development process before launching a new drug into the market. Several unique data sources are available for postmarketing PV [ 36 ].…”

Section: Data Mining For Pvmentioning

confidence: 99%

Role of Pharmacovigilance in India: An overview

Suke

Kosta²,

Negi

2015

OJPHI

View full text Add to dashboard Cite

Pharmacovigilance (PV) plays a key role in the healthcare system through assessment, monitoring and discovery of interactions amongst drugs and their effects in human. Pharmaceutical and biotechnological medicines are designed to cure, prevent or treat diseases; however, there are also risks particularly adverse drug reactions (ADRs) can cause serious harm to patients. Thus, for safety medication ADRs monitoring required for each medicine throughout its life cycle, during development of drug such as pre-marketing including early stages of drug design, clinical trials, and post-marketing surveillance. PV is concerns with the detection, assessment, understanding and prevention of ADRs. Pharmacogenetics and pharmacogenomics are an indispensable part of the clinical research. Variation in the human genome is a cause of variable response to drugs and susceptibility to diseases are determined, which is important for early drug discovery to PV. Moreover, PV has traditionally involved in mining spontaneous reports submitted to national surveillance systems. The research focus is shifting toward the use of data generated from platforms outside the conventional framework such as electronic medical records, biomedical literature, and patient-reported data in health forums. The emerging trend in PV is to link premarketing data with human safety information observed in the post-marketing phase. The PV system team obtains valuable additional information, building up the scientific data contained in the original report and making it more informative. This necessitates an utmost requirement for effective regulations of the drug approval process and conscious pre and post approval vigilance of the undesired effects, especially in India. Adverse events reported by PV system potentially benefit to the community due to their proximity to both population and public health practitioners, in terms of language and knowledge, enables easy contact with reporters by electronically. Hence, PV helps to the patients get well and to manage optimally or ideally, avoid illness is a collective responsibility of industry, drug regulators, clinicians and other healthcare professionals to enhance their contribution to public health. This review summarized objectives and methodologies used in PV with critical overview of existing PV in India, challenges to overcome and future prospects with respect to Indian context.

show abstract

Gathering and Exploring Scientific Knowledge in Pharmacovigilance

Cited by 16 publications

References 45 publications

Potential Drug−Drug Interactions in Infant, Child, and Adolescent Patients in Children’s Hospitals

Potential Drug−Drug Interactions in Infant, Child, and Adolescent Patients in Children’s Hospitals

Targets of drugs are generally and targets of drugs having side effects are specifically good spreaders of human interactome perturbations

Role of Pharmacovigilance in India: An overview

Contact Info

Product

Resources

About